Analyst Expectations for Portage Biotech's Future
Portfolio Pulse from Benzinga Insights
In the last quarter, Portage Biotech (NASDAQ:PRTG) received 4 bullish analyst ratings, with an average 12-month price target of $10.5, a decrease of 43.24% from the previous average price target of $18.50.
September 07, 2023 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Portage Biotech received 4 bullish analyst ratings in the last quarter, but its average 12-month price target decreased by 43.24% to $10.5.
The decrease in the average 12-month price target despite the bullish ratings indicates that analysts may have revised their expectations downwards for Portage Biotech. This could potentially lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100